The thrombosis-related diseases are one of the leading causes of illness and death in the
general population, and despite significant improvements in long-term survival due to …

The use of the direct oral anticoagulants dabigatran, rivaroxaban, apixaban and edoxaban
(DOACs) offers some major advantages over warfarin and other vitamin K antagonists …

In the absence of robust evidence to guide clinical decision-making, the optimal approach to
prevent stroke and systemic embolism in haemodialysis (HD) patients with atrial fibrillation …

Aims To compare the effectiveness and safety of off-label underdosed apixaban with on-
label standard dose apixaban in Asian patients with atrial fibrillation (AF). Methods and …

Direct Oral Anticoagulants (DOACs) require dose adjustment based on specific patient
characteristics, making them prone to incorrect dosing. The current study aimed to evaluate …

Objective The aim of this study was to assess the effect of moderate or severe renal
impairment on the pharmacokinetic (PK) properties of milvexian. Methods This open-label …

Although effective and safe, treatment with direct oral anticoagulants (DOAC) in atrial
fibrillation (AF) is still associated with thrombotic complications. Whether the measurement of …

In real-world clinical practice, underdosing, ie off-label use of reduced doses (RDs), of oral
factor Xa inhibitors (oFXaIs) is quite common in stroke prevention in non-valvular atrial …

Background The introduction of direct oral anticoagulants (DOAC) has resulted in a
paradigm shift in the management of venous thromboembolism (VTE). We evaluate the …

Atrial fibrillation/flutter (AF) and COVID-19 are associated with an elevated risk of arterial
and venous thrombosis. Whether preadmission oral anticoagulation (OAC) for AF reduces …